ARTICLE

CONVENTIONAL AND NOVEL TREATMENT STRATEGIES TO COMBAT COVID19 ALONG WITH REVIEW OF MOST AFFECTED COUNTRIES

  1. HOME
  2. ARTICLE

03 Pages : 25-32

http://dx.doi.org/10.31703/gdddr.2020(V-I).03      10.31703/gdddr.2020(V-I).03      Published : Dec 2020

Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries

Abstract

    This review illustrates a comparison of currently implemented strategies and the need of a novel technique to cure the COVID-19. Current strategies served a lot to cope up with the situation by decreasing the rate of fatalities i.e. some FDA approved drugs and giving immunity by the plasma proteins of cured patients, however these approaches could not eliminate the pandemic from the society emphasizing that some advance technology need to be considered in order to fight with SARS-COV-2 virus. CRISPR-Cas based approach to inactivate the virus before its fusion with host DNA has been successful in in-vitro studies performed at Stanford University along with SHERLOCK & MAMMOTH biosciences who were able to degrade 80 % viral genome. Here we have also done a literature review of major affected countries China, Italy, United states, and India.

    CRISPR-Cas, Cure, Covid-19, FDA, SARS-COV-2

    (1) Umair-Ul-Hassan
    Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
    (2) Rana Muhammad Awais Khan
    Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
    (3) Shafiq-Ur-Rehman
    Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
    (4) Amjad Khan
    Assistant Professor, Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Fulltext PDF

References

  • Coronavirus | 42Percent of patients in India between 21 and 40 years. (2020). India:
  • Shinghal, T. (2020). A Review of Coronavirus Disease- 2019 (COVID-19). Nature Public Health Emergency Collection, 281-286.
  • Edward Livingston, K. B. (2020). Coronavirus Disease 2019 (COVID-19) in Italy. Jama Network.
  • Statista. (2020). Coronavirus (COVID-19) death rate in Italy as of October 6, 2020, by gender and age group. Retrieved from Italy:
  • Erin K. Stokes, M., corresponding author,* Laura D. Zambrano, PhD,* Kayla N. Anderson, PhD, Ellyn P. Marder, DrPH, Kala M. Raz, MPH, Suad El Burai Felix, MPH, Yunfeng Tie, PhD, and Kathleen E. Fullerton, MPH. (2020). Coronavirus Disease 2019 Case Surveillance. Retrieved from United States:
  • Times, T. N. Y. (2020). Does Covid-19 Hit Women and Men Differently? U.S. Isn't Keeping Track.
  • Graziano Onder, G. R., Silvio Brusaferro. (2020). Case- Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. Jama Network.
  • Timothy R. Abbott, G. D., Yanxia Liu, Xueqiu Lin, Laine Goudy, Leiping Zeng, Augustine Chemparathy, Stephen Chmura, Nicholas S. Heaton, Robert Debs, Tara Pande, Drew Endy, Marie La Russa, David B. Lewis, Lei S. Qi. (2020). Development of CRISPR as a prophylactic strategy to combat novel coronavirus and influenza. bioRxiv. Worldometer. https://www.worldometers.info/coronavirus/c ountry/india/
  • Konwarh, R. (2020). Can CRISPR/Cas Technology Be a Felicitous Stratagem Against the COVID-19 Fiasco? Prospects and Hitches. Frontiers in Molecular Biosciences.
  • Zhi, Z. L. X. B. X. Z. (2020). The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. National Library of Medicine, 145-151.
  • Rai, D. (2020). Young Indians comprise more than half of confirmed Covid-19 cases. New Delhi:
  • Zunyou Wu, M., Jennifer M. McGoogan. (2020). Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Jama Network.
  • Saeid Chekani-Azar, E. G. M., Mastewal BIRHAN and Mahshad YOUSEFI. (2020). CRISPR/Cas9 gene editing technology and its application to the coronavirus. Journal of Life Science and Biomedicine.
  • Samarasinghe, D. A., Nalawansha, Kusal T. G. (2020). Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. ACS Publications, 790-800.

Cite this article

APA

    APA : Umair-Ul-Hassan., Khan, R. M. A., & Shafiq-Ur-Rehman. (2020). Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V(I), 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03

CHICAGO

    CHICAGO : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V (I): 25-32 doi: 10.31703/gdddr.2020(V-I).03

HARVARD

    HARVARD : UMAIR-UL-HASSAN., KHAN, R. M. A. & SHAFIQ-UR-REHMAN. 2020. Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries. Global Drug Design & Development Review, V, 25-32.

MHRA

    MHRA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. 2020. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V: 25-32

MLA

    MLA : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review, V.I (2020): 25-32 Print.

OXFORD

    OXFORD : Umair-Ul-Hassan, , Khan, Rana Muhammad Awais, and Shafiq-Ur-Rehman, (2020), "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries", Global Drug Design & Development Review, V (I), 25-32

TURABIAN

    TURABIAN : Umair-Ul-Hassan, , Rana Muhammad Awais Khan, and Shafiq-Ur-Rehman. "Conventional and Novel Treatment Strategies to Combat COVID-19 along with Review of most Affected Countries." Global Drug Design & Development Review V, no. I (2020): 25-32. https://doi.org/10.31703/gdddr.2020(V-I).03